Nesiritide for heart failure: impact on costs and complications

References

• Jessup M, Brozena S. Heart failure. N. Engl. J. Med.348, 2007–2018 (2003).
   PubMed Web of Science ®Google Scholar
• American Heart Association. 2002 Heart and Stroke Statistical Update. American Heart Association, TX, USA (2003).
   Google Scholar
• US Department of Health and Human Services. Health Care Finance Association (HCFA): MEDPAR Inpatient Hospital Datafile, Fiscal Year 1998. Bureau of Data Management and Strategy, Washington CD, USA (1999).
   Google Scholar
• O’Connell JB. The economic burden of heart failure. Clin. Cardiol.23(Suppl 3), 6–10 (2000).
   Web of Science ®Google Scholar
• Ramirez G, Ayers-Chastain CW, Bittle PA et al. Formulary restriction on antihypertensive drugs. Hosp. Ther.15(2), 205–221 (1990).
   Google Scholar
• Felker GM, Adams KF, Konstam MA, O'Connor CM, Gheorghiade M. The problem of decompensated heart failure: nomenclature, classification, and risk stratification. Am. Heart J.145, S18–S25 (2003).
   PubMed Web of Science ®Google Scholar
• Cuffe MS, Califf RM, Adams KF Jr et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA287, 1541–1547 (2002).
   PubMed Web of Science ®Google Scholar
• Steimle AE, Stevenson LW, Chelimsky-Fallick C et al. Sustained hemodynamic efficacy of therapy tailored to reduce filling pressures in survivors with advanced heart failure. Circulation96, 1165–1172 (1997).
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Cody RJ, Francis GS, McKenna WJ, Young JB, Bonow RO. Current medical therapy for advanced heart failure. Am. Heart J.135(6 Pt 2), S231–S248 (1998).
   Web of Science ®Google Scholar
• Ewy GA. Inotropic infusions for chronic congestive heart failure. Medical miracles or misguided medicinals? J. Am. Coll. Cardiol.33, 572–575 (1999).
   PubMed Web of Science ®Google Scholar
• Cuffe MS, Califf RM, Adams KF Jr et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA287, 1541–1547 (2002).
   PubMed Web of Science ®Google Scholar
• Silver MA, Horton DP, Ghali JK, Elkayam U. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. J. Am. Coll. Cardiol.39, 798–803 (2002).
   PubMed Web of Science ®Google Scholar
• Follath F, Cleland JG, Just H et al. for the Steering Committee and Investigators of the Levosimendan infusion versus Dobutamine (LIDO) Study. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet360, 196–202 (2002).
   PubMed Web of Science ®Google Scholar
• Cotter G, Metzkor E, Kaluski E et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet351, 389–393 (1998).
   PubMed Web of Science ®Google Scholar
• Fung HL, Bauer JA. Mechanisms of nitrate tolerance. Cardiovasc. Drugs Ther.8, 489–499 (1994).
   PubMed Web of Science ®Google Scholar
• Cohn JN, Franciosa JA, Francis GS et al. Effect of short-term infusion of sodium nitroprusside on mortality rate in acute myocardial infarction complicated by left ventricular failure: results of a Veterans Administration cooperative study. N. Engl. J. Med.306, 1129–1135 (1982).
   PubMed Web of Science ®Google Scholar
• Monrad ES, Baim DS, Smith HS, Lanoue AS. Milrinone, dobutamine, and nitroprusside: comparative effects on hemodynamics and myocardial energetics in patients with severe congestive heart failure. Circulation73(Suppl. III), III168–III174 (1986).
   PubMedGoogle Scholar
• Colucci WS, Elkayam U, Horton DP et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N. Engl. J. Med.343, 246–253 (2000).
   PubMed Web of Science ®Google Scholar
• Marcus LS, Hart D, Packer M et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation94, 3184–3189 (1996).
   PubMed Web of Science ®Google Scholar
• Yasue H, Yoshimura M. Natriuretic peptides in the treatment of heart failure. J. Card. Fail.2(Suppl. 4), S277–S285 (1996).
   PubMedGoogle Scholar
• Abraham WT, Lowes BD, Ferguson DA et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J. Card. Fail.4, 37–44 (1998).
   PubMedGoogle Scholar
• Jensen KT, Eiskjaer H, Carstens J, Pedersen EB. Renal effects of brain natriuretic peptide in patients with congestive heart failure. Clin. Sci.96, 5–15 (1999).
   PubMed Web of Science ®Google Scholar
• Burger AJ, Elkayam U, Neibaur MT et al. Comparison of the occurrence of ventricular arrhythmias in patients with acutely decompensated congestive heart failure receiving dobutamine versus nesiritide therapy. Am. J. Cardiol.88, 35–39 (2001).
   PubMed Web of Science ®Google Scholar
• Publication Committee for the VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA287, 1531–1540 (2002).
   PubMed Web of Science ®Google Scholar
• Young JB, Abraham WT, Stevenson LW, Horton DP. Results of the VMAC trial: vasodilation in the management of acute congestive heart failure. Circulation102, 2794a (2000).
   Google Scholar
• Peacock WF, Emerman CL, on behalf of the PROACTION Study Group. Safety and efficacy of nesiritide in the treatment of decompensated heart failure in observation patients (abstract 1027–89). J. Am. Coll. Cardiol.41(Suppl. A), 336A (2003).
   Google Scholar
• Yancy CW, Saltzberg M, Berkowitz RL, Horton DP, Silver MA. The FUSION Investigators. Management of patients with congestive heart failure after hospitalization: results from the Follow-Up Serial Infusions of Nesiritide (FUSION) trial (abstract 034). J. Card. Fail.9(Suppl. 1), S11 (2002).
   Google Scholar
• Burger AJ, Horton DP, Lejemtel T et al. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am. Heart J.144, 1102–1108 (2003).
   Web of Science ®Google Scholar
• de Lissovoy G, Stier DM, Ciesla G, Munger M, Burger AJ. Economic implications of nesiritide versus dobutamine in the treatment of patients with acutely decompensated congestive heart failure. Am. J. Cardiol.92, 631–633 (2003).
   PubMed Web of Science ®Google Scholar
• Hunter CB, Hilleman DE, Malesker MA, Holewinski CJ. Cost-effectiveness of nesiritide in acute decompensated heart failure (abstract 221). J. Am. Coll. Cardiol.8(Suppl. 4), S61 (2002).
   Google Scholar
• Lewis DA, Gurram NR, Abraham WT, Akers WS. Effect of nesiritide versus milrinone in the treatment of acute decompensated heart failure. Am. J. Health Syst. Pharm.60(Suppl. 4), S16–S20 (2003).
   Google Scholar
• Lenz TL, Foral PA, Malesker MA, Hunter CB, Hilleman DE. Impact of nesiritide on health care resource consumption and complications in patients with decompensated heart failure. Pharmacotherapy24, 1137–1146 (2004).
   PubMed Web of Science ®Google Scholar
• Chang R, Elatre WA, Heywood JT. Effect of nesiritide on length of hospital stay in decompensated heart failure (abstract 1085–71). J. Am. Coll. Cardiol.41(Suppl. A), 161A (2003).
   Google Scholar